Episodic syndromes that may be associated with migraine, previously named periodic syndromes, are a group of disorders characterized by recurrent transient attacks, followed by complete resolution of the symptoms, which occur in patients with migraine or with an increased risk of developing migraine. 1 In the International Classification of Headache Disorders, Third Edition (beta version), episodic syndromes include neurological syndromes (benign paroxysmal torticollis [BPT] and benign paroxysmal vertigo [BPV] ) and recurrent gastrointestinal disturbances, which gather various disorders with overwhelming digestive symptoms. 2 BPT is characterized by recurrent episodes of head tilt to one side, perhaps with slight rotation, which remit spontaneously. BPT occurs in infants and young children, with onset in the first year of life. 3 BPV is characterized by recurrent brief attacks of vertigo, occurring without warning and resolving spontaneously, in otherwise typically developing children; onset usually occurs at school age (later than BPT), although onset in adulthood has been reported. 4, 5 Benign tonic upward gaze (BTU) is an infantile-onset paroxysmal neurological disorder initially described in 1988 by Ouvrier and Billson. 6 BTU is characterized by episodes of variably sustained conjugate upward eye deviation with neck flexion, down-beating saccades in attempted downgaze, preserved horizontal eye movements, diurnal fluctuation of symptoms, frequent relief by sleep, exacerbation with febrile illnesses, varying degrees of ataxia, and usually negative investigations including electroencephalographic recording and cerebrospinal fluid neurotransmitters. Attacks improve within a couple of months or years, and between the attacks neurological examination is normal, with no deterioration during long-term follow-up.
Co-occurrence of BPT, BPV, and BTU has been described in the same patient or in patients from the same family, [7] [8] [9] suggesting a clinical continuum. Gene mutations in CACNA1A (which encodes the a-subunit of the neuronal P/Q-type calcium channel) have been reported in some cases of BTU, 8, 10, 11 BPT, 12, 13 or BPV, 7 also suggesting a common pathophysiological basis of these three episodic syndromes. Mutations of the CACNA1A gene were initially associated with familial hemiplegic migraine type 1, episodic ataxia 2, spino-cerebellar ataxia type 6 (Rajakulendran et al. 14 ), and recently in encephalopathic epilepsy. 15 The implication of mutations of the CACNA1A gene in the episodic syndromes, or the role of other genes, remains unclear. 13, 16 The comorbidities associated with BPT, BPV, and BTU also require further investigation. Although BPT and BPV are considered benign, 1, [17] [18] [19] psychomotor impairment, borderline cognitive abilities, and mild ataxia are detected in half of the patients with BTU. 6, [20] [21] [22] Here we describe the clinical, neuropsychological, and genetic characteristics of patients with BPT, BPV, and BTU, to better delineate the clinical relationships and pathophysiological links between these disorders and to assess the cognitive profile of these patients.
METHOD Patients
This cross-sectional study enrolled patients from 13 university hospitals in France between July 2011 and February 2016. The study was performed in accordance with the Declaration of Helsinki and approved by the Sud-M editerrann ee Ethical Committee. Written informed consent was obtained from the patients' parents or legal representatives for clinical data collection, genetic studies, and publication of the results.
Patients who met the following criteria were enrolled: (1) age ranging between 3 years and 18 years, allowing the evaluation of cognitive function; (2) episodes of BPT or BPV fitting the International Classification of Headache Disorders diagnosis criteria, 2 or episodes of BTU meeting criteria defined by Ouvrier and Billson. 20 Patients with other disorders that could have been responsible for episodic syndromes were excluded by investigations (brain magnetic cerebral imaging, electroencephalogram, metabolic screening).
Clinical data, learning abilities, and cognitive evaluation
The clinical data were collected from the medical file and during familial interview using a standardized protocol: medical history (with specific emphasis on perinatal events, psychomotor development, and occurrence of other episodic neurological disorders including episodic ataxia, hemiplegic or non-hemiplegic migraine [NHM]), clinical description of the paroxysmal episodes, neurological examination at inclusion, and familial history. Magnetic resonance imaging (MRI) data were reviewed by an experienced neuroradiologist (NL) and a paediatric neurologist (AR).
Standardized cognitive scales were administered according to age: Wechsler Preschool and Primary Scale of Intelligence, Third Edition for children under 7 years, Wechsler Intelligence Scale for Children, Fourth Edition for children between 7 and 16 years, and Wechsler Adult Intelligence Scale test for patients older than 16 years. Executive functions were assessed by simplified Rey figure for patients younger than 6 years of age and Rey figure for older patients. Six other cognitive items were specifically assessed: (1) specific assistance in mainstream school (services provided by the Ministry of Education in France, such as computer use or human assistance), (2) specialized education, (3) presence of learning disabilities, (4) attention deficiency, (5) motor hyperactivity, (6) needs for rehabilitation (speech, occupational, or psychomotor therapy). This information was collected according to the medical file and clinical assessment without dedicated scale.
As IQ testing was not available for all patients, and to complete the psychometric data by adaptative functioning data, we constructed composite criteria reflecting cognitive function, according to an algorithm that included a combination of the collected data. Patients with (1) Full-scale IQ below 70, or (2) one IQ subscore below 80 and at least two items among the list of six cognitive items, or (3) at least three items among the list of six were considered as having 'cognitive dysfunction'.
Genetic testing
Screening of CACNA1A was performed by sequencing and quantitative multiplex polymerase chain reaction of short fluorescent fragments for all included patients. In patients without CACNA1A mutation, sequencing of other genes involved in episodic neurological syndromes was performed, namely KCNA1, FGF14, and PRRT2 genes. 19, 23 When a mutation was identified in a patient, genetic testing was proposed to family members (symptomatic or non-symptomatic father and mother, and siblings or other relatives if symptomatic).
Statistical analysis
Patients' characteristics were presented using frequencies and proportions for categorical variables, median with interquartile range between the 25th centile and 75th centile (or mean and SD) and range (minimum-maximum) for continuous variables. Groups, defined by the presence of mutation, were compared using Student ' • These patients also have an increased risk of abnormal neurological examination and cognitive dysfunction.
• Gene mutations, especially in CACNA1A, were identified in 21% of the families.
• BPT, BTU, and BPV should not be regarded as benign.
• BPT, BTU, and BPV should be considered as part of the spectrum of a neurodevelopmental disorder.
was used. The statistical bilateral significance threshold was set at 5%. Statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
Fifty patients (48 index-cases and two familial-cases [patients 37 and 38, and patients 4 and 16]) were enrolled. The median age at inclusion was 6 years (interquartile range between the 25th centile and 75th centile: 4-9y; range 3-17y).
Episodic events Types of event
Among the 50 patients, BTU was diagnosed in eight, BPT in 26, and BPV in 26. Thirty-five patients had a pure phenotype-that is, only one type of episodic syndrome at the time of inclusion (apart from NHM): BPT (n=16), BPV (n=16), BTU (n=3). Fifteen patients (30%) exhibited concomitant or consecutive episodic neurological manifestations: BPT and BPV (n=9), episodic ataxia occurring after BTU (n=3), episodic ataxia occurring after BPT and NHM (n=1), hemiplegic migraine occurring after BPV (n=1), or a combination of BPT, episodic ataxia, and NHM (n=1). Migraine was reported in 12 patients, NHM in 11, and hemiplegic migraine in one (for details see Table SI , online supporting information).
Description of episodic phenotypes
The clinical characteristics of the periodic episodes of BTU, BPT, and BPV are described in Table SII (online  supporting information) . Age at onset. BPT was the earliest phenotype, with a median age at onset of 5 months. BTU occurred with a median age at onset of 8 months, and BPV had a median age at onset of 18 months. Frequency and duration of the attacks. The number of episodes during the first year or during the following years varied widely from 1 to 400 per year. However, approximately two-thirds of the patients suffered from one attack or less per month: respectively five out of seven patients with BTU, 19 out of 26 patients with BPT, and 16 out of 24 patients with BPV. The duration of the attacks was also highly variable. Accompanying signs and triggering factors. Truncal ataxia, with inability to stand up or to sit, was very frequent during the attacks of BPT (68%), BPV (60%), and BTU (50%). Fatigue was the most frequent precipitating factor. Sleep induced a clinical improvement in 40% of patients with BTU, 75% of patients with BPV, and 55% of patients with BPV.
Evolution
At the time of enrolment, 13 out of 47 patients were considered cured (Table SII) . All these patients exhibited a pure phenotype: three patients with BTU, eight patients with BPT, and two patients with BPV. Seven out of eight patients with BTU, 11 out of 22 patients with BPT, and three out of 25 patients with BPV were considered cured at the time of inclusion.
Neurocognitive assessment
As five patients exhibited a disorder potentially associated with neurological and/or intellectual disability, they were excluded from the neurocognitive analysis (Table SI) . Analysis of the neurocognitive assessment was performed in 45 patients (Table I and details in Table SI) .
Developmental milestones, learning abilities
Psychomotor development was delayed in 11 patients. Learning disabilities were described in 36% of the patients, including graphic function and/or reading difficulties in 21% and 24% of the patients respectively. Fifteen children required specific measures such as learning assistance at school and/or benefited from rehabilitation (especially speech therapy). Two patients were in an institution for children with intellectual disability.
Cognitive assessment
IQ testing was performed in 34 out of 45 patients, using the Wechsler Preschool and Primary Scale of Intelligence, Third Edition test for 16 patients and the Wechsler Intelligence Scale for Children, Fourth Edition test for 18 patients, according to age (Table I) . Full-scale IQ was non-interpretable in 12 patients, owing to a discrepancy (Fig. 1) . Analysis of IQ scores in the whole group of patients did not reveal a specific pattern of disability.
The composite criterion constructed using six items described more accurately the cognitive abilities of the patients, as it was not only restricted to IQ test results but also included assistance at school and rehabilitation. With this criterion, cognitive dysfunction was observed in 12 out of 45 patients: five out of eight patients exhibited BTU, three out of 22 patients exhibited BPT, and five out of 25 patients exhibited BPV (case 14 exhibited attacks of BPT and then PBV) ( Table I and Table SI ). The Rey complex figure test was performed in 16 (32%) patients. The copy score was lower than 50% in eight patients. Memory score was lower than 50% in seven patients.
Neurological assessment
Among the 14 patients with abnormal neurological examination at inclusion, cerebellar signs were present in five, hypotonia in six, pyramidal tract signs in three, and nystagmus in four (including one patient with associated cerebellar symptoms and one patient with cerebellar and pyramidal signs).
All patients had a normal cerebral MRI at the time of diagnosis. Patient 36 had a normal MRI at 5 years of age, and a second MRI performed at 11 years 8 months showed cerebellar atrophy (see below).
Genetic analysis
Genetic results were available in all but one patient (not performed in case 33 as the analysis of CACNA1A, KCNA1, FGF14, and PRRT2 genes was negative for her brother, case 32). Among the 48 families, a mutation was identified in 11 patients from 10 families (Tables I and II) : mutations in the CACNA1A gene in eight families (nine included patients), and mutation in the KCNA1 and FGF14 genes in one family respectively. CACNA1A mutations were identified in four out of eight patients with BTU and in four out of 26 patients with BPT. The three patients with a mixed phenotype of BTU and episodic ataxia harboured a CACNA1A mutation. Among the 26 patients with BPV, a mutation was identified in three: KCNA1 mutation in one patient with isolated BPV, FGF14 mutation in one patient with isolated BPV, and CACNA1A mutation in one patient with a complex phenotype characterized by BPV from 9 months to 7 years, hemiplegic migraine from 10 years, cognitive dysfunction, and cerebellar atrophy disclosed on the second MRI (patient 36).
Family history
A family history of episodic syndrome was recorded in nine out of 48 families, two harbouring CACNA1A mutation, one harbouring FGF14 mutation, and one harbouring KCNA1 mutation (Table II) . In the five other families, medical history showed intrafamilial variability of episodic events and/or chronic neurological dysfunction. Illustrative cases are shown in Figure 2 . Family history of NHM was reported in 28 out of 48 families.
Illustrative cases
Family of patient 39 (Fig. 2a) . The proband was referred for brief and daily episodes of vertigo with onset at 18 months of age; his neurological examination and cognitive functions between the attacks were normal upon enrolment in the study. His father and paternal grandfather reported second-decade-onset attacks of vertigo, but they never asked for medical assistance until the proband was referred. Autosomal dominant mutation in KCN1A was confirmed in these three-generational individuals. Family of patient 43 (Fig. 2b) . From the age of 2 years, the proband exhibited episodes of vertigo with nausea, vomiting, and unsteady gait lasting 2 to 4 days. These attacks were triggered by fever related to intercurrent benign infections and recurred three or four times a year. Neurological examination and cognitive status were normal. His father experienced two prolonged episodes of vertigo at 8 years and 31 years of age. Clinical examination at 37 years disclosed horizontal nystagmus and upper limbs' rest tremor. A great-aunt experienced fever-triggered vertigo, and a great-uncle exhibited hand tremor. Genetic testing identified an autosomal dominant point mutation in FGF14 in the patient and his father; the other relatives were not tested. Family of patient 3 (Fig. 2c) . The proband exhibited BTU between the age of 8 months and 22 months. Psychomotor impairment was noticed from the first year, and clinical follow-up disclosed early-onset cerebellar signs that progressively improved, mimicking 'congenital ataxia'. At last examination (9y 1mo), the young female was hypotonic with stato-kinetic mild ataxia. She had cognitive deficiency (Full-scale IQ=40), and she was in an institution for intellectually disabled children. Her elder sister (not included in this series) presented psychomotor delay, learning disabilities, mild mental deficiency (Full-scale IQ=60), and attacks of episodic ataxia lasting 30 minutes from the age of 13 years. Between the attacks, examination disclosed discrete nystagmus. Both females harboured a CACNA1A mutation. The mother did not carry the mutation. The father refused genetic testing. Family of patient 34 (Fig. 2d) . From 4 months of age, the proband exhibited stereotyped episodes of pallor with nausea and vertigo recurring twice a year. His mother had yearly attacks of hemiplegic migraine from the age of 8 years. Genetic testing did not disclose any mutation.
Associations
The identification of a CACNA1 mutation was significantly associated with the presence of BTU (p=0.03) and episodic ataxia (p<0.01), as well as several cognitive items (language delay, learning disabilities, specific measures at school, therapy) and the composite cognitive dysfunction criteria (p=0.01); CACNA1A mutation was negatively associated with BPV (p=0.01) ( Table III) . The presence of two or more different episodic neurological syndromes (multiple episodic events) in relatives was significantly associated with a CACNA1 mutation (p=0.04). We found no association with (1) the presence of a mixed phenotype in the proband, (2) an onset before 1 year of age, or (3) an abnormal neurological examination.
Cognitive dysfunction was not significantly correlated with the occurrence of BPT, compared with BTU or BPV (p=0.45, p=0.09, and p=0.22 respectively). Cognitive disability was significantly associated with the occurrence of episodic ataxia (p=0.02).
DISCUSSION
This study of 50 patients with BPT, BPV, or BTU shows that these episodic disorders are frequently associated with a variety of neurological findings, cognitive issues, and some specific genetic defects. Motor and/or language delay was reported in 11 children. Abnormal neurological examination, especially hypotonia and cerebellar signs, was observed in more than one-third of the patients. Cognitive profile analysis showed an increased rate of patients with borderline IQ (23% vs 6.7% in the general population). The combinatory algorithm, which allows a more pragmatic approach of global cognitive function of each patient, showed that 62% of the patients with BTU had cognitive disabilities, which is concordant with previous reports. 20 We also demonstrated that 14% of the patients with BPT and 20% of the patients with BPV exhibited cognitive dysfunction. Rosman reported gross motor function delay in five out of 10 patients with BPT, but cognitive abilities were not specifically assessed 9 and never studied in larger series. The cognitive function of patients with BPV has never been investigated, although higher indices of behavioural and emotional symptoms have been suggested. 24 A trend towards the association of cognitive dysfunction with BTU is suggested, although the BTU subset of patients is small. Later occurrence of episodic ataxia is significantly correlated with cognitive impairment. In our series, the prevalence of psychomotor delay, abnormal neurological findings, and cognitive dysfunction calls into question whether it is appropriate to label BTU, BPT, and BPV as 'benign conditions'.
Our study also highlights that one-third of the patients exhibited concomitant syndromes or evolution from one episodic syndrome to another, suggesting that they are part of a common spectrum. It is noteworthy that seven patients among the 26 with BPT or BPV had a mixed phenotype still ongoing at last follow-up. This point confirms that BPT in some cases is not a self-limited syndrome but might evolve to BPV. 9, 25 Previous series of BTU patients did not report mixed phenotype. As they focused on BTU, associated episodic manifestations might have been underdiagnosed. 6, 10, 20, 26 NHM was reported in a quarter of our patients, which is above the classic prevalence of 10% to 20% in childhood, 27 but below the 33% to 100% reported in BPV 28, 29 or BPT. 1, 9 As migraine onset commonly occurs in late childhood, and given the young age of our patients, the association of migraine in our population might be underestimated. A pathogenic mutation was identified in 10 out of 48 families. The CACNA1A gene was the most frequently involved, and its mutations were correlated with BTU, episodic ataxia, language delay, cognitive dysfunction, and family history with multiple types of episodic event in the family. Pathogenic CACNA1A mutations have been described occasionally in single case reports of patients with BPT, BPV, and BTU. 10 Our results confirm the role of CACNA1A mutations in a subgroup of patients with BTU and BPT, especially when cognitive dysfunction and multiple types of episodic event in the family are associated. Moreover, although our study was limited by the small number of patients with BTU, we hypothesize that, in some cases, BTU might represent the first sign of a wider phenotype including episodic neurological manifestations and chronic symptoms (developmental delay, cerebellar ataxia, cognitive dysfunction) related to CACNA1A mutation.
Our study confirms the existence of atypical cases that expand the clinical spectrum associated with CACNA1A mutations (one patient with a phenotype mimicking congenital ataxia with mental deficiency; one patient with progressive cerebellar atrophy). 30 Mutation of the KCNA1 gene, involved in episodic ataxia type 1, was identified in a three-generational family whose phenotype was described as 'paroxysmal vertigo'. An FGF14 gene mutation was identified in a patient with prolonged attacks of vertigo triggered by fever and permanent nystagmus. These two families highlight that clinical boundaries between attacks of vertigo or episodes of ataxia are not so distinct, especially in children, and emphasize the clinical and molecular overlaps between paroxysmal vertigo and episodic ataxia.
BPT, BPV, and BTU are rare disorders, and only short series of patients have been reported, in contrast to the fairly large number of patients enrolled in this study. We tried to collect an exhaustive set of data, not only on clinical description of episodic events but also on cognitive status and familial history, and completed this with genetic analysis. The clinical information about the acute attacks is largely concordant with previous descriptions, and in this respect the episodic syndromes in our population are typical. 1, 19, 20 Given the young median age of our population, learning disabilities and the proportion of patients considered cured might have been underestimated. 25, 27, 28, 31 On the other hand, the retrospective methodology, multiple sites of inclusion, and the examiners might have introduced some bias. Finally, despite our large series of patients, our statistical results should be interpreted cautiously owing to the small sample size in each subgroup.
CONCLUSION
Although the attacks of BTU, BPT, and BPV are transient and eventually resolve during childhood, the mono-symptomatic course is rare: some patients develop an additional type of paroxysm, some have chronic neurological deficits, and some demonstrate developmental delay and intellectual disability or learning difficulties. Attacks of BTU, BPT, and BPV might represent a very small part of a more complex phenotype including various episodic manifestations, chronic neurological clinical signs, and cognitive dysfunction, whose spectrum may be considered as a neurodevelopmental disorder. Shared pathophysiological processes have been elucidated in some patients: mutations of the CACNA1A gene might be implicated, especially when the patients suffer from BTU or BPT, or when cognitive dysfunction and positive family history are associated.
